Literature DB >> 17869516

Reliability and feasibility of the six minute walk test in subjects with myotonic dystrophy.

Marie Kierkegaard1, Anna Tollbäck.   

Abstract

The objective was to describe test-retest reliability and feasibility of the six minute walk test in adult subjects with myotonic dystrophy type 1. Twelve subjects (28-68 years, mean 44) performed three six minute walk tests on two occasions, one week apart. Relative reliability was high (ICC(2.1)=0.99) and absolute reliability values were low (standard error of measurement 12 m, repeatability 33 m). Feasibility was investigated in a sample of 64 subjects (19-70 years, mean 43). Fifty-two subjects were able to perform two tests on the same day. Subjects with severe proximal weakness had difficulties performing repeated tests. A practice trial followed by a second test on the same day can be recommended for most subjects, and the best test should be used for evaluations. In conclusion, even though the study sample was small, the present study indicates that the six minute walk test is reliable and feasible in subjects with myotonic dystrophy type 1.

Entities:  

Mesh:

Year:  2007        PMID: 17869516     DOI: 10.1016/j.nmd.2007.08.003

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  26 in total

1.  Chronic exercise mitigates disease mechanisms and improves muscle function in myotonic dystrophy type 1 mice.

Authors:  Alexander Manta; Derek W Stouth; Donald Xhuti; Leon Chi; Irena A Rebalka; Jayne M Kalmar; Thomas J Hawke; Vladimir Ljubicic
Journal:  J Physiol       Date:  2019-01-30       Impact factor: 5.182

2.  Myotonic dystrophy health index: Correlations with clinical tests and patient function.

Authors:  Chad Heatwole; Rita Bode; Nicholas E Johnson; Jeanne Dekdebrun; Nuran Dilek; Katy Eichinger; James E Hilbert; Eric Logigian; Elizabeth Luebbe; William Martens; Michael P Mcdermott; Shree Pandya; Araya Puwanant; Nan Rothrock; Charles Thornton; Barbara G Vickrey; David Victorson; Richard T Moxley
Journal:  Muscle Nerve       Date:  2015-12-29       Impact factor: 3.217

3.  Physical function and mobility in children with congenital myotonic dystrophy.

Authors:  Evan M Pucillo; Deanna L Dibella; Man Hung; Jerry Bounsanga; Becky Crockett; Melissa Dixon; Russell J Butterfield; Craig Campbell; Nicholas E Johnson
Journal:  Muscle Nerve       Date:  2017-02-13       Impact factor: 3.217

4.  Possible clinical outcome measures for clinical trials in patients with multiple sclerosis.

Authors:  Myla D Goldman; Robert W Motl; Richard A Rudick
Journal:  Ther Adv Neurol Disord       Date:  2010-07       Impact factor: 6.570

5.  Open-label trial of recombinant human insulin-like growth factor 1/recombinant human insulin-like growth factor binding protein 3 in myotonic dystrophy type 1.

Authors:  Chad R Heatwole; Katy J Eichinger; Deborah I Friedman; James E Hilbert; Carlayne E Jackson; Eric L Logigian; William B Martens; Michael P McDermott; Shree K Pandya; Christine Quinn; Alexis M Smirnow; Charles A Thornton; Richard T Moxley
Journal:  Arch Neurol       Date:  2010-09-13

6.  Efficacy of focal mechanic vibration treatment on balance in Charcot-Marie-Tooth 1A disease: a pilot study.

Authors:  Costanza Pazzaglia; F Camerota; M Germanotta; E Di Sipio; C Celletti; L Padua
Journal:  J Neurol       Date:  2016-05-13       Impact factor: 4.849

7.  MRI/MRS evaluation of a female carrier of Duchenne muscular dystrophy.

Authors:  Sean C Forbes; Donovan J Lott; Richard S Finkel; Claudia Senesac; Barry J Byrne; H Lee Sweeney; Glenn A Walter; Krista Vandenborne
Journal:  Neuromuscul Disord       Date:  2012-10-01       Impact factor: 4.296

8.  Facioscapulohumeral muscular dystrophy functional composite outcome measure.

Authors:  Katy Eichinger; Chad Heatwole; Stanley Iyadurai; Wendy King; Lindsay Baker; Susanne Heininger; Amy Bartlett; Nuran Dilek; William B Martens; Michael Mcdermott; John T Kissel; Rabi Tawil; Jeffrey M Statland
Journal:  Muscle Nerve       Date:  2018-01-30       Impact factor: 3.217

9.  Two-minute versus 6-minute walk distances during 6-minute walk test in neuromuscular disease: Is the 2-minute walk test an effective alternative to a 6-minute walk test?

Authors:  J W Witherspoon; R Vasavada; R H Logaraj; M Waite; J Collins; C Shieh; K Meilleur; C Bönnemann; M Jain
Journal:  Eur J Paediatr Neurol       Date:  2018-10-23       Impact factor: 3.140

10.  Validity of the 6 minute walk test in facioscapulohumeral muscular dystrophy.

Authors:  Katy Eichinger; Chad Heatwole; Susanne Heininger; Nikia Stinson; Carly Matichak Stock; Carla Grosmann; Kathryn R Wagner; Rabi Tawil; Jeffrey M Statland
Journal:  Muscle Nerve       Date:  2016-12-05       Impact factor: 3.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.